All In Biotech

Drug Trial Radar · NCT04400201

A Clinical Study of Remimazolam Tosilate in Patients Undergoing Bronchoscopy

A Phase III Clinical Study Evaluating the Efficacy and Safety of Remimazolam Tosilate Compared to Propofol in Patients Undergoing Bronchoscopy

Last checked: Nov 20, 2026Latest source record: Aug 22, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 330 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

330

Actual

Start

Jun 15, 2020

Primary completion

Oct 28, 2020

Study completion Oct 30, 2020

Sponsor

Sponsor type
Industry
First posted
May 22, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Single group
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multicenter, randomized, single-blind, active controlled, parallel group study comparing remimazolam tosilate to propofol in patients undergoing bronchoscopy.

Conditions

  • Sedation

Interventions

  • Remimazolam TosilateDrug

    Intravenous injection at a dose of 0.3mg/kg for sedation induction and continuous intravenous infusion at an initiative dose of 1 mg/kg/h for sedation maintenance.

  • PropofolDrug

    Intravenous injection at a dose of 1.5\~2.5mg/kg for sedation induction and continuous intravenous infusion at the dose of 0\~12 mg/kg/h for sedation maintenance

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage (%) of participants who experienced successful sedation in undergoing bronchoscopy in each groupTime frame: From the onset of administration of the study drug to removal of bronchoscope on Day 1 of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.